With the long-term business alliance that began between Pfizer and Mylan at the start of the year, Mylan has begun transferring the rights for its products, excluding consignment products, to Pfizer. The companies will begin selling joint brands displaying the logos of both companies from May 2013. The launch of immunosuppressive agent tacrolimus, anti-allergy agent olopatadine, transdermal analgesic loxoprofen, and antibacterial eye-drop levofloxacin are planned for June 2013, and the companies continue to develop more than 125 products. Pfizer is responsible for marketing and sales while Mylan handles development and manufacturing. Approximately 200 sales reps from Mylan have been moving to Pfizer since January. (Click Here For More – Japanese Language
)